Errors in Figures 1, 2, and 4 have been discovered in the below referenced article and corrected in the present erratum.
Figure 1.
Valbenazine studies. Valbenazine dose groups were pooled as follows: “low dose” (50 mg/day and 100/50 mg/day [KINECT], 50 mg/day [KINECT 2], and 40/day mg [KINECT 3]); and “high dose” (75 mg/day [KINECT 2], 80 mg/day [KINECT 3]). Participants who received valbenazine 25 mg/day in KINECT 2 were not included in the pooled analyses. Participants randomized to valbenazine 80 mg/day in KINECT 3 received 40mg/day for 1 week.
Figure 2.
AIMS total score mean change from baseline to week 6. ***P < 0.001 versus placebo.
Figure 3.
Estimation of AIMS MCID. Based on all participants who met CGI‐TD response criteria regardless of treatment (valbenazine or placebo).
Stacy M, Sajatovic M, Kane JM, Cutler AJ, Liang GS, O'Brien CF, Correll CU. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Mov Disord. 2019;34(8):1203‐1209. doi: 10.1002/mds.27769.
We apologize for this omission and any inconvenience this has caused.